CardioMEMS HF System

For pulmonary artery pressure monitoring

Patient Selection

Patient Selection & Assessment

Selecting the Right Patient

The CardioMEMS™ HF System is indicated for patients with:¹

NYHA Class II or Class III heart failure; and
One heart failure hospitalization in the past 12 months; and/or
Have elevated natriuretic peptides

The CardioMEMS HF System is contraindicated for patients with:

An inability to take dual antiplatelet or anticoagulants for one-month post implant

Patient Selection Resources

This document provides information to select heart failure patients who would benefit most from the CardioMEMS HF System, along with BNP thresholds.

Patient Candidate Considerations Tool

Patients who most commonly receive the CardioMEMS HF System are those on GDMT and those who exhibit any of the following:²

Fluid volumes that are hard to know or manage
Challenging physical assessment
Is a patient with HFpEF or HFrEF
Compliant with heart failure medical care
Would benefit from remote monitoring if they live far from a clinic

Note: The CHAMPION trial specifically excluded patients with American College of Cardiology/ American Heart Association stage D heart failure who needed advanced therapies (i.e., left ventricular assist device, transplant or inotropic support). Even if inotropic support improved heart failure symptoms, a patient would still be defined as stage D, with refractory heart failure.²

CardioMEMS HF System Patient Approach with Philip B. Adamson, MD, MSC, FACC (06:01)

In this video, Philip B. Adamson, M.D., MSc, FACC, reviews essential tips for approaching patients about their symptoms and engaging in conversation about the CardioMEMS HF System.

CardioMEMS HF System Patient Approach with Jamie Pelzel, MD (07:43)

In this video, Jamie Pelzel, MD, reviews essential tips to approaching patients about their symptoms and engaging in conversation about the CardioMEMS HF System.

CardioMEMS HF System Patient Approach with Stephanie Preister, CNP (05:46)

In this video, Stephanie Preister, CNP, leads a discussion with patients about the CardioMEMS HF System and patient compliance.

Reimbursement & Coding

Manuals & Resources

Customer Service

References

Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomized controlled trial. The Lancet. 2021;398:991-1001.
Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M., Costanzo, M. R., Stevenson, L. W., …Yadav, J. S., for the CHAMPION Trial Study Group. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666. https://dx.doi.org/10.1016/S0140-6736(11)60101-3

MAT-2006770 v6.0

CARDIOVASCULAR

CardioMEMS HF System

For pulmonary artery pressure monitoring

Patient Selection & Assessment

Selecting the Right Patient

The CardioMEMS™ HF System is indicated for patients with:¹

The CardioMEMS HF System is contraindicated for patients with:

Patient Selection Resources

Patient Candidate Considerations Tool

Patients who most commonly receive the CardioMEMS HF System are those on GDMT and those who exhibit any of the following:²

References

POLICIES & ADVISORIES

HEALTHCARE PROFESSIONALS

PATIENTS & CAREGIVERS

CARDIOVASCULAR

CardioMEMS HF System

For pulmonary artery pressure monitoring

Patient Selection & Assessment

Selecting the Right Patient

The CardioMEMS™ HF System is indicated for patients with:¹

The CardioMEMS HF System is contraindicated for patients with:

Patient Selection Resources

Patient Candidate Considerations Tool

Patients who most commonly receive the CardioMEMS HF System are those on GDMT and those who exhibit any of the following:²

References

POLICIES & ADVISORIES

HEALTHCARE PROFESSIONALS

PATIENTS & CAREGIVERS

STAY CONNECTED